Your browser doesn't support javascript.
loading
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan, Tamara L; Wei, Wei; Ludkovski, Olga; Morais, Carlos L; Guedes, Liana B; Jamaspishvili, Tamara; Lopez, Karen; Hawley, Sarah T; Feng, Ziding; Fazli, Ladan; Hurtado-Coll, Antonio; McKenney, Jesse K; Simko, Jeffrey; Carroll, Peter R; Gleave, Martin; Lin, Daniel W; Nelson, Peter S; Thompson, Ian M; True, Lawrence D; Brooks, James D; Lance, Raymond; Troyer, Dean; Squire, Jeremy A.
Afiliação
  • Lotan TL; Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Wei W; Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Ludkovski O; MD Anderson Cancer Center, Houston, TX, USA.
  • Morais CL; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
  • Guedes LB; Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Jamaspishvili T; Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Lopez K; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
  • Hawley ST; Pathology, UCSF, San Francisco, CA, USA.
  • Feng Z; Canary Foundation, Palo Alto, CA, USA.
  • Fazli L; MD Anderson Cancer Center, Houston, TX, USA.
  • Hurtado-Coll A; Vancouver Prostate Centre, Vancouver, BC, Canada.
  • McKenney JK; Vancouver Prostate Centre, Vancouver, BC, Canada.
  • Simko J; Pathology, Cleveland Clinic, Cleveland, OH, USA.
  • Carroll PR; Pathology, UCSF, San Francisco, CA, USA.
  • Gleave M; Urology, UCSF, San Francisco, CA, USA.
  • Lin DW; Urology, UCSF, San Francisco, CA, USA.
  • Nelson PS; Canary Foundation, Palo Alto, CA, USA.
  • Thompson IM; Urology, University of Washington, Seattle, WA, USA.
  • True LD; Urology, University of Washington, Seattle, WA, USA.
  • Brooks JD; Oncology, University of Washington, Seattle, WA, USA.
  • Lance R; Pathology, University of Washington, Seattle, WA, USA.
  • Troyer D; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Squire JA; Urology, UTHSCSA, San Antonio, TX, USA.
Mod Pathol ; 29(8): 904-14, 2016 08.
Article em En | MEDLINE | ID: mdl-27174589
PTEN loss is a promising prognostic and predictive biomarker in prostate cancer. Because it occurs most commonly via PTEN gene deletion, we developed a clinical-grade, automated, and inexpensive immunohistochemical assay to detect PTEN loss. We studied the sensitivity and specificity of PTEN immunohistochemistry relative to four-color fluorescence in situ hybridization (FISH) for detection of PTEN gene deletion in a multi-institutional cohort of 731 primary prostate tumors. Intact PTEN immunostaining was 91% specific for the absence of PTEN gene deletion (549/602 tumors with two copies of the PTEN gene by FISH showed intact expression of PTEN by immunohistochemistry) and 97% sensitive for the presence of homozygous PTEN gene deletion (absent PTEN protein expression by immunohistochemistry in 65/67 tumors with homozygous deletion). PTEN immunohistochemistry was 65% sensitive for the presence of hemizygous PTEN gene deletion, with protein loss in 40/62 hemizygous tumors. We reviewed the 53 cases where immunohistochemistry showed PTEN protein loss and FISH showed two intact copies of the PTEN gene. On re-review, there was ambiguous immunohistochemistry loss in 6% (3/53) and failure to analyze the same tumor area by both methods in 34% (18/53). Of the remaining discordant cases, 41% (13/32) revealed hemizygous (n=8) or homozygous (n=5) PTEN gene deletion that was focal in most cases (11/13). The remaining 19 cases had two copies of the PTEN gene detected by FISH, representing truly discordant cases. Our automated PTEN immunohistochemistry assay is a sensitive method for detection of homozygous PTEN gene deletions. Immunohistochemistry screening is particularly useful to identify cases with heterogeneous PTEN gene deletion in a subset of tumor glands. Mutations, small insertions, or deletions and/or epigenetic or microRNA-mediated mechanisms may lead to PTEN protein loss in tumors with normal or hemizygous PTEN gene copy number.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imuno-Histoquímica / Biomarcadores Tumorais / Hibridização in Situ Fluorescente / PTEN Fosfo-Hidrolase Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imuno-Histoquímica / Biomarcadores Tumorais / Hibridização in Situ Fluorescente / PTEN Fosfo-Hidrolase Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos